WHWK vs NRXP vs JPM vs AXSM vs ATAI

For growth investors, Atai Beckley N.

V (ATAI) is the stronger pick with 1228% revenue growth year-over-year, versus -72. 5% for Whitehawk Therapeutics Inc (WHWK). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +277. 9%, compared to -97. 9% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: AXSM returned +35. 5% versus NRXP's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Axsome Therapeutics, Inc.

(AXSM) is the lower-risk stock at 0. 63β versus NRx Pharmaceuticals, Inc. 's 2. 05β — meaning NRXP is approximately 224% more volatile than AXSM relative to the S&P 500. On balance sheet safety, Atai Beckley N. V (ATAI) carries a lower debt/equity ratio of 1% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atai Beckley N.

V (ATAI) is pulling ahead at 1228% versus -72. 5% for Whitehawk Therapeutics Inc (WHWK). On earnings-per-share growth, the picture is similar: Whitehawk Therapeutics Inc grew EPS 86. 0% year-over-year, compared to -212. 9% for Atai Beckley N. V. Over a 3-year CAGR, ATAI leads at 159. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -161. 4% for Atai Beckley N. V — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -24. 4% for ATAI. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ATAI: 206.

1% to $12. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. WHWK, NRXP, AXSM, ATAI do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, NRXP: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WHWK (Healthcare) and NRXP (Healthcare) and JPM (Financial Services) and AXSM (Healthcare) and ATAI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WHWK is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; AXSM is a mid-cap high-growth stock; ATAI is a small-cap high-growth stock. JPM pays a dividend while WHWK, NRXP, AXSM, ATAI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.